Impact of Postnatal Corticosteroid Use on Neurodevelopment at 18 to 22 Months' Adjusted Age: Effects of Dose, Timing, and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants

• Published in: Pediatrics (Evanston) 2009-03, Vol.123 (3), p.e430-e437
• Main Authors: Wilson-Costello, Deanne, Walsh, Michele C, Langer, John C, Guillet, Ronnie, Laptook, Abbot R, Stoll, Barbara J, Shankaran, Seetha, Finer, Neil N, Van Meurs, Krisa P, Engle, William A, Das, Abhik, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
• Format: Article
• Language: English
• Subjects: Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - adverse effects; Birth weight; Bronchopulmonary Dysplasia - mortality; Bronchopulmonary Dysplasia - prevention & control; Cerebral palsy; Cerebral Palsy - chemically induced; Cerebral Palsy - diagnosis; Cerebral Palsy - mortality; Clinical trials; Cohort Studies; Developmental Disabilities - chemically induced; Developmental Disabilities - diagnosis; Developmental Disabilities - mortality; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Dose-Response Relationship, Drug; Follow-Up Studies; Gestational Age; Humans; Infant; Infant, Extremely Low Birth Weight; Infant, Newborn; Lung diseases; Motor ability; Pediatrics; Prospective Studies; Regression analysis; Sensation Disorders - chemically induced; Sensation Disorders - diagnosis; Sensation Disorders - mortality; Steroids; Survival Rate
• ISSN: 0031-4005; 1098-4275
• DOI: 10.1542/peds.2008-1928

Postnatal steroid use decreases lung inflammation but increases impairment. We hypothesized that increased dose is associated with increased neurodevelopmental impairment, lower postmenstrual age at exposure increases impairment, and risk of bronchopulmonary dysplasia modifies the effect of postnatal corticosteroid. Steroid dose and timing of exposure beyond 7 days was assessed among 2358 extremely low birth weight infants nested in a prospective trial, with 1667 (84%) survivors examined at 18 to 22 months' postmenstrual age. Logistic regression tested the relationship between impairment (Bayley Mental Developmental Index/Psychomotor Developmental Index of 0.5 as high risk, n = 2336 (99%) for days of life 4-7). Three hundred sixty-six (16%) neonates were steroid-treated (94% dexamethasone). Treated neonates were smaller and less mature; 72% of those treated were at high risk for bronchopulmonary dysplasia. Exposure was associated with neurodevelopmental impairment/death. Impairment increased with higher dose; 71% dead or impaired at highest dose tertile. Each 1 mg/kg dose was associated with a 2.0-point reduction on the Mental Developmental Index and a 40% risk increase for disabling cerebral palsy. Older age did not mitigate the harm. Treatment after 33 weeks' postmenstrual age was associated with greatest harm despite not receiving the highest dose. The relationship between steroid exposure and impairment was modified by the bronchopulmonary dysplasia risk, with those at highest risk experiencing less harm. Higher steroid dose was associated with increased neurodevelopmental impairment. There is no "safe" window for steroid use in extremely low birth weight infants. Neonates with low bronchopulmonary dysplasia risk should not be exposed. A randomized trial of steroid use in infants at highest risk is warranted.